Science 37 Holdings (Nasdaq:SNCE) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SNCE Overzicht aandelen

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Meer informatie

SNCE fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 91.4% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 17.47% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $35M )

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft minder dan 1 jaar cash runway

+ 1 meer risico

Science 37 Holdings, Inc. Concurrenten

IsoPlexis

NasdaqGS:ISO

US$30.3m

Bionano Genomics

NasdaqCM:BNGO

US$25.6m

ImmunoPrecise Antibodies

NasdaqGM:IPA

US$10.8m

Rapid Micro Biosystems

NasdaqCM:RPID

US$47.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Science 37 Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$5.75
52 Week Hoogtepunt	US$12.96
52 Week Laag	US$3.73
Bèta	0.57
11 maand verandering	1.23%
3 maanden verandering	30.39%
1 Jaar Verandering	30.86%
33 jaar verandering	-97.22%
5 jaar verandering	n/a
Verandering sinds IPO	-97.14%

Recent nieuws en updates

Recent updates

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Dec 18

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Apr 17

Science 37, Syapse team for faster patient enrollment in cancer trials

Aug 18

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Aug 11

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

May 13

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Apr 11

Science 37: Pioneering Decentralized Clinical Trials

Jan 02

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Nov 04

Rendement voor aandeelhouders

	SNCE	US Life Sciences	US Markt
7D	0.3%	5.3%	2.2%
1Y	30.9%	4.8%	32.6%

Rendement versus industrie: SNCE overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 4.8 % opleverde.

Rendement versus markt: SNCE kwam overeen met de US markt, die het afgelopen jaar een rendement opleverde van 32.6 %.

Prijsvolatiliteit

Is SNCE's price volatile compared to industry and market?
SNCE volatility
SNCE Average Weekly Movement	15.6%
Life Sciences Industry Average Movement	8.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SNCE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van SNCE is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	460	Dave Coman	www.science37.com

Science 37 Holdings, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Science 37 Holdings zich tot de beurswaarde?
SNCE fundamentele statistieken
Marktkapitalisatie	US$34.67m
Inkomsten(TTM)	-US$124.65m
Inkomsten(TTM)	US$60.26m

0.6x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is SNCE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SNCE resultatenrekening (TTM)
Inkomsten	US$60.26m
Kosten van inkomsten	US$38.14m
Brutowinst	US$22.12m
Overige uitgaven	US$146.77m
Inkomsten	-US$124.65m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-20.67
Brutomarge	36.71%
Nettowinstmarge	-206.85%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SNCE op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

SNCE Overzicht aandelen

Beloningen

Risicoanalyse

Science 37 Holdings, Inc. Concurrenten

NasdaqGS:ISO

US$30.3m

NasdaqCM:BNGO

US$25.6m

NasdaqGM:IPA

US$10.8m

NasdaqCM:RPID

US$47.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

Recent updates

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

Price target decreased by 51% to US$13.83

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

New major risk - Share price stability

Forecast to breakeven in 2026

Science 37 Holdings Regains Compliance with Minimum Closing Bid Price Requirement for Continued Listing on NASDAQ Capital Market

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Science 37 Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$64k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Science 37 Holdings Announces Nasdaq Approves an Additional 180 Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Requirement

Consensus estimates of losses per share improve by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Price target decreased by 9.4% to US$1.81

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. (NasdaqGM:SNCE) acquired Life Sciences Platform of Vault Health.

Science 37 Holdings Receives A Deficiency Notification Letter from Nasdaq Regarding Minimum Bid Price

Consensus revenue estimates fall by 15%

Price target decreased to US$3.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Science 37 Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Science 37 Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Science 37 Holdings, Inc. Announces Board Changes

Science 37®Holdings, Inc. Announces Changes to its Board

Science 37 Holdings, Inc. Appoints Michael Shipton as Chief Commercial Officer

Science 37 Holdings, Inc. and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Consensus forecasts updated

Science 37, Syapse team for faster patient enrollment in cancer trials

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Science 37 Holdings, Inc. Provides Revenue Guidance for Year Ending December 31, 2022

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

Consensus estimates of losses per share improve by 72%

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

Science 37® Announces NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

First quarter 2022 earnings: Revenues exceed analyst expectations

Science 37 Holdings, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

Price target decreased to US$11.33

Science 37 Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Science 37 Holdings, Inc. Adds Shaalan Beg to Its Global Management Team